Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (NASDAQ/CSE/FRA: QNTM) has announced the closing of the first tranche of its previously announced offering from December 5, 2024. The company has issued 500 Debenture Units raising CAD $500,000. The proceeds will be allocated to the company's ongoing business model development and general working capital. Securities issued in this tranche are subject to a four-month and one-day statutory hold period from issuance. The company's obligations under the Debentures are no longer collaterally secured by general security.
Quantum BioPharma (NASDAQ: QNTM) announced that the safety review committee has recommended proceeding with the second cohort dosing in their Phase 1 Multiple Ascending Dose clinical trial for Lucid-21-302. The trial, conducted through subsidiary HUGE Biopharma Australia, is evaluating safety and pharmacokinetics of Lucid-21-302 in healthy adult participants. The recommendation follows a review of safety and pharmacokinetic data from the first cohort. The second cohort dosing is expected to begin within days.
Quantum BioPharma (NASDAQ:QNTM) has announced a non-brokered private placement offering of up to 5,000 convertible debenture units at $1,000 per unit, aiming to raise up to $5 million. Each unit includes a $1,000 secured convertible debenture and 80 class B share purchase warrants.
The debentures will mature in 36 months with a 1.25% monthly interest rate, payable quarterly. They are convertible into class B shares at $6.25 per share. The warrants allow holders to purchase additional class B shares at $7.00 per share within 5 years. The proceeds will support business development and working capital. The company also settled $43,825.17 in debt through the issuance of 7,500 shares at $5.84 per share.
Quantum BioPharma (NASDAQ:QNTM), formerly FSD Pharma, has filed a US$700M+ lawsuit against CIBC World Markets, RBC Dominion Securities and others for alleged market manipulation and share price spoofing. The company has assembled legal teams working on a contingency basis, meaning no upfront costs for the company.
The company is actively inviting shareholders who experienced losses during the relevant period to join the case by sharing details of their trading losses and personal impact. Information can be submitted via email or through the company's website on the 'Quantum vs Banks' page, which will be updated periodically with case progress.
Quantum BioPharma (NASDAQ:QNTM) announces the commencement of sentinel dosing for its Phase 1 multiple ascending dose clinical trial of Lucid-21-302 in Australia. The study aims to evaluate the safety and pharmacokinetics of Lucid-21-302 in healthy adult participants, marking a significant step toward Phase 2 efficacy trials for multiple sclerosis treatment. The company has also retained several firms for market awareness and investor relations, including Agoracom ($25,000 CAD), Independent Trading Group ($7,500 CAD monthly), Buyins ($15,000 USD), and Stockjock ($15,000 USD).
Quantum Biopharma (Nasdaq: QNTM) has filed a market manipulation lawsuit against CIBC World Markets and RBC Dominion Securities. The complaint alleges that defendants engaged in 'spoofing' - placing sell orders they didn't intend to fill - to artificially lower the stock price over a four-year period. This manipulation allegedly occurred more than a thousand times, causing significant harm to both the company and shareholders. Quantum Biopharma claims it was forced to sell shares at artificially depressed prices during this period and is now seeking damages to compensate for losses.
Quantum BioPharma (NASDAQ:QNTM) has filed a complaint in the U.S. District Court for the Southern District of New York against CIBC World Markets, RBC Dominion Securities, and others. The lawsuit alleges that between January 1, 2020, and August 15, 2024, the defendants engaged in market manipulation through "spoofing" techniques, violating securities laws. Quantum BioPharma is seeking damages exceeding $700 million USD.
The company has posted a copy of the complaint on its website for public access. Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis. The complaint alleges that the defendants' actions artificially depressed Quantum BioPharma's stock price, harming both the company and its retail investors.
Quantum BioPharma's stock price has fallen from over $460 USD per share in January 2020 to $7.55 USD as of October 18, 2024, reducing its market cap from nearly $1 billion to less than $15 million. The company believes other banks/brokers may be involved in the alleged manipulation but has not named them at this time.
Quantum BioPharma (NASDAQ: QNTM) has filed a US federal lawsuit against CIBC World Markets, RBC Dominion Securities, and others, seeking damages exceeding $700 million USD for alleged stock price manipulation through spoofing. The lawsuit, filed on October 20, 2024, in the Southern District of New York, claims violations of the Securities Exchange Act of 1934 between January 1, 2020, and August 15, 2024.
The company alleges that the defendants used spoofing techniques to artificially depress Quantum BioPharma's stock price. In January 2020, the stock traded over $460 USD per share with a market cap near $1 billion, but as of October 18, 2024, it closed at $7.55 USD per share with a market cap under $15 million.
Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis. The company remains open to dialogue for an amicable solution with the involved banks and brokers.
Quantum BioPharma (NASDAQ:QNTM) has filed a $700 million USD lawsuit against CIBC World Markets, RBC Dominion Securities, and others in the US District Court for the Southern District of New York. The lawsuit alleges market manipulation through 'spoofing' techniques between January 1, 2020, and August 15, 2024, violating securities laws.
The company claims the defendants manipulated QNTM's stock price, causing significant harm to shareholders. Quantum's stock price fell from over $460 USD in January 2020 to $7.55 USD on October 18, 2024, reducing its market cap from nearly $1 billion to less than $15 million.
Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis. The company remains open to dialogue for an amicable solution with the involved parties.
Quantum BioPharma (NASDAQ: QNTM) has provided an update on Celly Nutrition Corp.'s signing of a Master Distribution Agreement with FUSION Distribution Group. This agreement covers Puerto Rico, The Caribbean, and parts of Central and South America. Celly Nutrition is launching unbuzzd™, an innovative beverage designed to support alcohol metabolism and promote alertness.
The partnership with FUSION, a leading brand incubator and distributor in the region, will introduce unbuzzd™ to new markets. The product is available on Amazon in Ready-to-Mix (RTM) powder sticks, with Ready-to-Drink (RTD) cans coming soon. FUSION's distribution network includes major retailers like Walmart, Walgreens, CVS, and Costco.
Celly Nutrition's CEO, John Duffy, formerly of Coca-Cola, and co-chair Gerry David, ex-CEO of Celsius Holdings, view this partnership as a significant opportunity for expansion in key vacation destinations where alcohol consumption is common.